Form 4: BeOne CEO Sells $9M in Shares Under 10b5-1 Plan

BeOne Medicines Ltd. CEO John Oyler sold 27,803 American Depositary Shares for approximately $9.06 million through a pre-arranged Rule 10b5-1 trading plan.

Summary

• John Oyler, CEO and Director of BeOne Medicines Ltd., sold a total of 27,803 American Depositary Shares (ADS) on September 16, 2025.
• The sales were executed through multiple transactions at weighted average prices ranging from $324.1176 to $327.78 per ADS.
• The total proceeds from these sales amounted to approximately $9,057,782.02.
• Each American Depositary Share represents 13 Ordinary Shares.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Oyler on March 12, 2025.
• Following these transactions, Mr. Oyler directly owns 0 American Depositary Shares.
• Mr. Oyler continues to directly own 7,450,894 Ordinary Shares and indirectly owns 9,545,000 Ordinary Shares through a Roth IRA PENSCO trust account.
• He disclaims beneficial ownership of additional Ordinary Shares held by the P&O Trust (481,533), a grantor retained annuity trust (7,722,480), Oyler Investment LLC (28,204,115), and The John Oyler Legacy Trust (102,188).

Sentiment

Score: 5

Explanation: The sale of shares by the CEO is a neutral event due to being pre-planned under a Rule 10b5-1 trading plan, which mitigates concerns about opportunistic selling. However, it still represents a reduction in direct equity exposure.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-determined transaction rather than a reaction to recent company news, which can mitigate concerns about opportunistic selling.

Negatives

• A significant sale of shares by a CEO, even under a 10b5-1 plan, could be perceived negatively by some investors as it reduces direct equity exposure.

Risks

• Investor perception risk: While pre-planned, a large insider sale could still lead to speculation or negative sentiment if not fully understood by the market.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Comparison to Industry Standards

• NA

Related Party Transactions

• John Oyler disclaims beneficial ownership of 481,533 Ordinary Shares held by the P&O Trust, whose beneficiaries include his child.
• He disclaims beneficial ownership of 7,722,480 Ordinary Shares held in a grantor retained annuity trust, where his father is a trustee.
• He disclaims beneficial ownership of 28,204,115 Ordinary Shares held by Oyler Investment LLC, where 99% of the interest is owned by a grantor retained annuity trust with his father as trustee.
• He disclaims beneficial ownership of 102,188 Ordinary Shares held by The John Oyler Legacy Trust for the benefit of his minor child.

Stakeholder Impact

• Shareholders: May observe the CEO's reduction in direct equity holdings, though the pre-planned nature of the sale under Rule 10b5-1 typically lessens negative interpretations.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Keywords

BeOne Medicines, ONC, John Oyler, CEO, Director, SEC Form 4, Insider Trading, Stock Sale, American Depositary Shares, ADS, Rule 10b5-1, Equity Transaction